Zydus Lifesciences has announced a strategic partnership with CVS Caremark to add its diabetes drug portfolio, including Zituvio, Zituvimet, and Zituvimet XR tablets, to CVS Caremark's template formulary. This move strengthens Zydus’ foothold in the US market and enhances access to affordable, high-quality diabetes medications for patients.

Key Highlights

• Products Added to Template Formulary:

The agreement includes Zituvio (sitagliptin), Zituvimet (sitagliptin and metformin hydrochloride), and Zituvimet XR (sitagliptin and metformin hydrochloride extended-release tablets), approved by the USFDA for type 2 diabetes treatment.

• Effective Date:

CVS Caremark will incorporate these medications into its formulary starting January 1, 2025.

• Strategic Investment:

Zydus Lifesciences aims to strengthen its portfolio of differentiated products in the US market through this partnership.

• Template Formulary Explained:

A template formulary is a continually updated list of medications, technologies, and products curated by experts and based on evidence-based medicine. It helps guide the diagnosis, treatment, and preservation of health, ensuring patients have access to effective therapies.

Insights from Leaders
Punit Patel, President & CEO of Zydus Pharmaceuticals USA Inc., emphasized the significance of this partnership:
“This relationship validates Zydus' strategic investments in our new drug application portfolio and sets the stage for expanding our differentiated product offerings in the US.”
He highlighted CVS Caremark’s patient-centric approach and commitment to making high-quality medications more accessible.

Impact on Type 2 Diabetes Care
The Zituvio product range, which combines sitagliptin and metformin hydrochloride, is designed to improve glycemic control in adults with type 2 diabetes when used alongside diet and exercise. This partnership is expected to enhance patient access to affordable diabetes treatments, reducing financial burdens while improving health outcomes.